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Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substan- 
tial burden on society, the research activity in BD is much smaller than its economic impact 
appears to demand. There is a consensus that the accurate identification of the underlying 
pathophysiology for BD is fundamental to realize major health benefits through better treat- 
ment and preventive regimens. However, to achieve these goals requires coordinated action 
and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, 
and rapid translation of research findings into development and testing of better and more spe- 
cific treatments. To this end, we here propose that only a large-scale coordinated action can 
be successful in integrating international big-data approaches with real-world clinical inter- 
ventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, 
which could bring government, industry and philanthropy together in common cause. A global 
initiative for BD research would come at a highly opportune time given the seminal advances 
promised for our understanding of the genetic and brain basis of the disease and the obvious 
areas of unmet clinical need. Such an endeavour would embrace the principles of open science 
and see the strong involvement of user groups and integration of dissemination and public in- 
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volvement with the research programs. We believe the time is right for a step change in our 
approach to understanding, treating and even preventing BD effectively. 
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY 









































































































p  . Introduction 
ipolar disorder (BD) has been classically depicted as the 
resence of alternating episodes of mood disturbances of 
pposite polarity (hypomania/mania versus depression) in- 
erspersed with periods of well-being (also defined as free 
ntervals) ( Grande et al., 2016 ). It is more than that. This
escription of episodic BD fails to include those presen- 
ations where clinical course has a chronic irregular pat- 
ern, including rapid cycling ( Koukopoulos et al., 2013 ) 
nd enduring subthreshold symptoms ( Bonnín et al., 2019 ) 
hat exert a higher toll in terms of long-term disabil- 
ty ( Arvilommi et al., 2015 ). Indeed, only a longitudinal
erspective can fully account for the suffering endured 
y patients and their relatives, and the substantial socio- 
conomic burden of BD: a recent prospective study of in-
ividuals with a BD diagnosed in youth, showed the signifi- 
antly worse psychosocial functioning when mood symptoms 
ere persistent (i.e. a chronic course) ( Hower et al., 2019 ;
cott et al., 2014 ). These features translate into the high
ocio-economic costs and decreased quality of life associ- 
ted with BD ( Cloutier et al., 2018 ; Gustavsson et al., 2011 ).
n Europe, mood disorders, including BD, are the most costly 
ental health conditions with an estimate of more than 
120 billion due to high direct healthcare costs and even 
igher indirect costs ( Gustavsson et al., 2011 ). Contributing
actors to this figure are the high prevalence in the general
opulation (around 4% considering the whole BD spectrum) 
 Grande et al., 2016 ), the early age of onset of the disor-
er ( Bauer et al., 2015 ), the premature mortality ( Plana-
ipoll et al., 2019 ), the number of disability-adjusted life
ears (DALYs) ( Ferrari et al., 2016 ), and the high rates
f substance abuse ( Zorrilla et al., 2015 ) and psychiatric
 Krishnan, 2005 ) and medical comorbidities ( Sinha et al.,
018 ) associated with BD. In summary, BD represents a ma-
or healthcare and socio-economic challenge. We believe 
he time is right for a step change in our approach to un-
erstanding, treating and even preventing BD effectively. 
There is a consensus that the accurate identification of 
he underlying pathophysiology for BD is fundamental to re- 
lize major health benefits through better acute and pre- 
entive treatments ( Bauer et al., 2018 ). BD is perhaps best
onceived to be an umbrella term for a variety of underlying
athologies which might be reflected by different biomark- 
rs and which might call for different treatments in the
ense of precision medicine. Risk prediction in BD, which 
ould inform prevention and stratification strategies, is sim- 
larly lacking ( Vieta et al., 2018 ). Novel approaches are
eeded to provide solutions to these problems. Many have 
uestioned the traditional way mental health research has 
een conducted, often based on “silos” with little interac- 
ion and even conflict between disciplines ( Holmes et al.,
018 ). There is the need for a truly multidisciplinary ap-
roach that brings together basic science research (com- 
uter science, mathematics/statistics, genetics), with dif- Downloaded for Anonymous User (n/a) at Aalborg Hospital fr
For personal use only. No other uses without permission.erent health professions (medicine, psychology), social sci- 
nces, and patient/advocate perspectives ( Scott et al., 
018 ). There is a clear demand for greater patient involve-
ent . Patients will need to help shape the scientific and
thical challenges that will directly concern them and the
ives of their families ( Maassen et al., 2018a ). Thus, by in-
egrating excellent multidisciplinary scientists and patient 
xperts, this new research approach will produce syner- 
ies and deliver major added value, with impact beyond the
tandard grant funding periods. 
In this paper, the Bipolar Disorders Network of the Euro-
ean College of Neuropsychopharmacology (ECNP) suggests 
 series of priorities, a manifesto, for the development
f future research initiatives in the area of BD. These
ecommendations will highlight approaches to boost the 
iscovery of the neurobiological underpinnings of BD and 
uggest an integrated approach to transition of these find-
ngs into discovery of new more specific treatments. We
ave selectively reviewed the evidence of the neurobiolog- 
cal underpinnings of BD, selected what we argue are the
ost significant remaining challenges, including the limited 
ransition of research findings into better diagnostics and 
reatment of BD. We describe how big data and related
esearch approaches can improve BD discoveries, focusing 
n the translation to clinically relevant information, and 
he potential role in precision medicine. The final part
utlines a roadmap for the creation of a Global Bipolar
isorder Foundation, which could coordinate international 
ig data approaches and integrate with real-world clinical 
nterventions. This will be a fundamental step as big data
an be instrumental in advancing BD research. The key re-
earch questions that could be addressed by the “big data”
pproach are: 1) Stratifying treatment response: who will 
espond to mood stabilized given baseline clinical genetic 
nd brain imaging phenotype? 2) Predicting outcome: who 
ill have life-time episode and who will develop rapid cy-
ling? 3) Developing new treatment: How can better insight
nto disease biology and treatment effect determinants 
elp drug development/drug repurposing in BD. Indeed, 
he goal is to obtain unique synergy by providing relevant
linical data for new analytical approaches and integrate 
ig data results in a clinical trial network for development
f personalized treatment regimens. This has been made 
ossible by recent technical developments allowing high 
hroughput, large scale genetic and brain imaging data 
ollection, as well as novel clinical information communica- 
ion technology (ICT) tools for efficient, user based clinical
ssessments. 
. Role of the patient community 
erspective 
 recent survey of over 6,000 individuals living with de-
ression and BD from the Depression and Bipolar Supportom ClinicalKey.com by Elsevier on September 03, 2020.
 Copyright ©2020. Elsevier Inc. All rights reserved.


















































































































Alliance and the Milken Institute ( Altimus, 2019 ) showed
that patients want improved treatments. However, the way
that patients define successful outcomes may not align with
the traditional goals of researchers and research agency
programs. The survey identified the ability to have an in-
dependent and self-determined life as the top priority. Only
20% of respondents identified the reduction of traditional
symptoms of BD as a measure of wellness. How we measure
outcomes must respect patient expectations and views of
what really matters. To do so, we need better integration
of individuals with BD in the planning of research programs.
This will assist researchers in incorporating consumer per-
spectives (patients and advocates) patient related outcome
measures (PROMS) ( Calvert et al., 2018 ) and personal re-
covery targets ( Jonas et al., 2012 ) in the repertoire of re-
sponse/outcome measures. Patients also placed a high pri-
ority on understanding why they developed BD as well as
objective diagnostic measures. 
Medical research and treatment call for practical solu-
tions of ethical problems. Genetic and behavioural profiling
may play an important part in improving the understanding
of BD, just as it has in other diseases. However, psychiatric
disorders are still stigmatizing: this demands particular sen-
sitivity in research design and implementation that must be
informed by the perspectives of people living with the dis-
order. 
There is also inconsistency between the expectations of
clinicians and researchers and the preferences of patients
and their relatives in assessing the quality of care for BD
patients in mental health services ( Maassen et al., 2018b ;
Skelly et al., 2013 ). Specifically, the implementation of best
practice guidelines does not necessarily improve quality of
care from the patient perspective ( Skelly et al., 2013 ).
Other surveys have highlighted the importance of gathering
individuals’ experiences on various aspects of BD, including
treatment ( Davenport et al., 2018 ; Maassen et al., 2017 ).
Indeed, Davenport et al. (2018) show that even psycholog-
ical interventions in BD often fail to recognize the individ-
ual as having agency in their recovery. Generally, empha-
sis needs to be paid to overall functional outcome, mor-
bidity and quality of life rather than just symptom-based
outcomes proximal to treatment delivery. 
Overall, these findings suggest that patient preference is
crucial to target and refine interventions at a clinical level,
and to make policy related to organization of healthcare
services and research funding. Indeed, seminal research in
BD has come from initiatives, such as those of the registries,
that have seen the merging of clinical care and research in-
volvement of users ( Chengappa et al., 2003 ; Hajek et al.,
2005 ; Kupfer et al., 2002 ). Dissemination of research find-
ings as well as of clinical guidelines, should be available
for patients, as recently exemplified for individuals with BD
treated with lithium ( Tondo et al., 2019 ). 
3. Causal factors – the ‘polygenic 
architecture’ and interplay with environment 
BD is a complex genetic disorder with a heritability esti-
mated at 60–95% ( Kieseppä et al., 2004 ; Lichtenstein et al.,
2009 ; McGuffin et al., 2003 ). The genetic architecture of
BD is determined by the effects of multiple genes (i.e.Downloaded for Anonymous User (n/a) at Aalborg Hospital from
For personal use only. No other uses without permission. C‘polygenic’) in combination with environmental factors
( Sullivan et al., 2017 ). To date, only a small fraction of the
heritability and the polygenic architecture of BD has been
determined ( Sklar et al., 2011 ; Stahl et al., 2019 ). This is
largely attributable to inadequately powered sample sizes
of genetic studies ( Sullivan et al., 2017 ). Another concern
is that since the samples are mainly restricted to the Euro-
pean population, the generalizability of the genetic findings
across populations may be questionable. 
The large fraction of heritability accounted for by com-
mon genetic variants with small effects ( Sklar et al., 2011 ;
Stahl et al., 2019 ) poses considerable challenges to ana-
lytical methods and sample size. Despite the assembly of
very large GWAS samples, the proportion of identified phe-
notypic variance is only close to 8% in BD ( Stahl et al., 2019 ).
Although larger sample sizes will increase GWAS statistical
power, small genetic effects are difficult to detect with tra-
ditional statistical methods due to the burden of multiple
testing. Moreover, the power of GWAS is largely dependent
on the level of polygenicity of the phenotype; high poly-
genicity leads to lower genetic effects per locus at a fixed
heritability, making loci harder to detect ( Holland et al.,
2016 ). Heterogeneity also dramatically reduces the power
to detect significant associations ( Manchia et al., 2013b ).
Novel biostatistical tools may help discover more of the ge-
netic architecture underlying highly polygenic disorders like
BD ( Smeland et al., 2019 ). For example, accumulating ev-
idence indicates that some genetic loci are more likely to
harbour causal effects than others; as examples the coding
and regulatory regions ( Schork et al., 2013 ) and loci associ-
ated with two phenotypes (pleiotropy) ( Schork et al., 2013 ).
This knowledge can be exploited with biostatistical tools
incorporating auxiliary genetic information which substan-
tially increase statistical power ( Andreassen et al., 2013a ,
2013 b; Schork et al., 2013 ; Wang et al., 2016 ). 
An international large-scale genetic consortium (Psy-
chiatric Genetics Consortium; PGC https://www.med.unc.
edu/pgc/ ) is successfully collaborating to implement these
approaches for the discovery of the genetic causes of
psychiatric disorders ( Sullivan, 2009 ; Sullivan et al., 2017 ).
The Bipolar Disorder Working group ( https://www.med.
unc.edu/pgc/pgc- workgroups/bipolar- disorder/ ) includes
nearly 300 scientists across the world, and thanks to in-
ternational large-scale genotyping efforts, current sample
sizes are close to 40,000 cases and 220,000 controls.
Preliminary results presented at the World Congress of
Psychiatric Genetics (WCPG) in 2019 demonstrated more
than 60 genetic loci to be associated with BD (Mullins et al.
in preparation ). However, detailed clinical information
and longitudinal data are largely missing. Longitudinal
cohorts are particularly suited to aid the discovery of
novel genetic and environmental factors that, in interplay,
might contribute to BD ( Grande et al., 2016 ; Vieta et al.,
2018 ). This is exemplified by the role of substance use,
such as cannabis, that represents a risk factor for BD
( Grande et al., 2016 ), and that might further interplay
with polygenic burden ( Aas et al., 2018 ). The interplay
between genetic predisposition and environmental factors
can be discovered by the multidisciplinary integration of
large samples with relevant data and analytical tools, as
suggested in the Nordic countries ( Njølstad et al., 2019 ).
As the environmental factors are potentially modifiable, ClinicalKey.com by Elsevier on September 03, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.























































































































he implementation of preventive strategies could become 
 real possibility. Finally, the causal role of protective 
enetic and environmental factors (resilience factors) 
emains largely unknown, although physical activity, sleep 
abits and certain diets ( Campbell and Campbell, 2019 ; 
oga et al., 2019 ; Pancheri et al., 2019 ) are correlated with
educed risk. 
. Impact of heterogeneity and the need to 
mprove phenotyping: big data and 
nformation communication technology 
D occurs with episodes of different severity and duration, 
ith varying predominance of polarity (more mania than 
epression, or, more commonly, more depression than ma- 
ia) and different degrees of chronicity of residual symp- 
oms (usually depressive) ( Grande et al., 2016 ; Vieta et al.,
018 ). Moving along such a mood disorder spectrum from
nipolar disorder – not the topic of this review – to BD type II
ith predominantly depressive polarity to BD type I disorder 
ith predominantly manic polarity goes along with chang- 
ng polygenic risk scores ( Coleman et al., 2019 ). Therefore,
recise clinical phenotyping is essential and to capture the 
elevant properties may require dense measurement. The 
ost obvious approach is to measure what we see and what
atients tell us; this allows us to define operational criteria
or identifying key features (or symptoms). The use of op-
rational definitions of mental states was adopted by anal- 
gy with the physical sciences use of operational definitions 
for example, of mass or energy). It dates from 1980 and
he publication of the Diagnostic and Statistical Manual of 
ental Disorders (DSM)-III as the basis for diagnosis and clas- 
ification in psychiatry. It represented a radical move away 
rom trying to classify mental illness with reference to the
eaning or psychological origin of the patients’ symptoms. 
ather, DSM classification created broad categories based on 
igns and symptoms. In BD the lifetime occurrence of mania 
esulted in different types, based on the intensity of manic 
ymptoms: BD type I requires an episode of mania, BD type
I requires an episode of hypomania and there is also a group
f conditions where manic symptoms are definitely present 
ut do not meet the criteria for an episode of mania or hypo-
ania. These categories capture some of the heterogeneity 
f the illness course ( Kapczinski et al., 2014 ) and the valid-
ty of the BD diagnosis, in terms of reliability and longitu-
inal stability, has in part been supported by the success of
he molecular genetic project ( Stahl et al., 2019 ). However,
any of the genes associated with BD are also associated 
ith other psychiatric disorders ( Cross-Disorder Group of 
he Psychiatric Genomics Consortium, 2019 ), just as its co- 
orbidity (with e.g. anxiety, impulse control disorders, and 
ddictions) would have predicted. This indicates that the 
sychiatric diagnostic categories defined by DSM and ICD- 
1 ( Stein et al., 2020 ) criteria do not capture distinct ge-
etic aetiologies, in contrast to neurological disorders that 
re defined by both symptoms and, recently, pathobiologi- 
al criteria ( Brainstorm Consortium, 2018 ). The time is right
o accept the challenge of transforming the traditional diag- 
ostic map of BD into something that reflects our emerging
nderstanding of its aetiology. Downloaded for Anonymous User (n/a) at Aalborg Hospital fr
For personal use only. No other uses without permission.A key limiting factor in the study of the phenotype of BD is
he absence of very large, longitudinally well-characterised 
atient cohorts. Given the lack of reliable disease biomark-
rs ( Carvalho et al., 2016 ), BD can only be diagnosed
y physicians/psychologists through subjective physician- 
atient interactions without recourse to objective labora- 
ory, imaging, or pathological testing. As described, im- 
ortant advances in our understanding of the pathophys- 
ology of BD have come from international consortia and
ollaborative efforts pooling and merging large databases 
nd samples of genetic and neuroimaging data. However, 
wo important limitations have hampered these efforts: one 
s the poor granularity of the clinical phenotype, and the
ther is the cross-sectional nature of the data. Although ef-
orts are being made to understand genetics, neuroimaging, 
nd biomarkers as reflecting dynamic processes, longitudi- 
al clinical studies are still in their infancy ( Kessing et al.,
017 ). 
Hence, although the scientific community has been able 
uccessfully to pool thousands of DNA and brain imaging
amples ( Nunes et al., 2018 ; Stahl et al., 2019 ), most of
hose biological samples go along with quite inadequate 
henotypic data (often only age, sex and diagnosis). Dis-
ussing the limitations of our official diagnostic systems 
DSM-5, ICD-11) is beyond the scope of this article, but it
s quite obvious that much more detail in describing and
nderstanding the mechanisms underlying symptoms and 
igns of the disorder will be essential. Initiatives such as
he Research Domain Criteria (RDoC) ( Insel et al., 2010 ),
romote a dimensional rather than a categorical approach 
o neuropsychiatric research and may explain basic mech- 
nisms underlying simple behaviours. The strong pleiotropy 
hat affects BD and most mental disorders ( Andlauer et al.,
019 ; Lee et al., 2019 ) and the difficulties of harmoniz-
ng biomarker information from multiple and heterogeneous 
ources such as different MRI scanners and laboratories is 
ery similar to the difficulties of collecting phenotypic data
rom different sites in a reliable way. Indeed, psychopathol-
gy is culturally sensitive and harmonizing this kind of data
s not an easy task, but this is perhaps the greatest unmet
eed if we really want to understand human behaviour and
ts anomalies. This may especially help our understanding 
f juvenile as compared with adult-pattern presentations of 
D. 
In addition, large scale phenotyping may include blood 
iomarkers, which can now be obtained for low cost.
here are several promising types of blood-based biomark- 
rs including as oxidative, neurotrophic, and inflammation 
arkers which may be involved in BD ( Fries et al., 2020 ;
osenblat and McIntyre, 2016 ). Furthermore, recent high- 
hroughput assessments of neurophysiological markers have 
lso been developed, such as easy to use EEG equipment and
ther tools for assessment of brain function ( Maggioni et al.,
017 ). By building large training samples, these factors can
e added to the models, and validated in independent test
ohorts. 
One of the greatest barriers to improving clinical in-
ormation has been, perhaps surprisingly, the cost; it is 
ay less expensive to perform brain scans or sophisticated
lood tests to large samples of people than to do thor-
ugh, fine-grained assessments by well-trained, experts in 
sychopathology (most large studies, such as epidemiology om ClinicalKey.com by Elsevier on September 03, 2020.
 Copyright ©2020. Elsevier Inc. All rights reserved.















































































































surveys, use students or volunteers to assess potential pa-
tients). As the RDoC initiative bears fruit ( Ahmed et al.,
2018 ), the phenotype may be seen in a less arbitrary light
than traditional phenomenology. However, the detailed col-
lection of clinical data may still be the only way to reconcile
psychopathology with biomarkers, phenotype and genotype
( Hidalgo-Mazzei et al., 2016 ). This could be of relevance
also for randomized clinical trials in BD. The enormous costs
related to the large sample sizes needed to reach adequate
statistical power have a negative impact on their feasibility.
Conversely, dense coverage of the longitudinal phenotypic
variation in BD patients trialled for a specific intervention
(e.g. ICT), could increase the signal to noise ratio, reduc-
ing the need for large sample size and facilitating the re-
alization of these fundamental studies. Furthermore, ran-
domized clinical trials are primarily designed to decrease
confounding and, in some instances, restricted sampling or
other design elements can lead to a loss of external valid-
ity. As such, pragmatic trials and observational studies are
needed to determine the comparative effectiveness of pu-
tative personalised treatments in real-world settings, to de-
fine their impact on outcomes that patients identify as im-
portant to them and to clarify potential mediators of any
benefits that these interventions may bring in day to day
practice. 
Fortunately, BD is very well suited for large scale screen-
ing by patients themselves using digital technology and
ICT tools ( Faurholt-Jepsen et al., 2019 ; 2018 ; Hidalgo-
Mazzei et al., 2018 ). Furthermore, exploiting secure ques-
tionnaires and secure storage ( Bauer et al., 2017 ) allows
health services to monitor personal perception of core psy-
chiatric disease symptomatology. Combining ICT tools with
genotyping technology provides a unique opportunity to
leverage existing biobanks and healthcare registries to sub-
stantially increase patient cohort sample sizes for BD. These
resources will be highly useful for large scale recruitment
and discovery of novel modifiable risk factors, identifying
interactions between genes and environmental triggers in
BD, and to facilitate clinical trials. Furthermore, ICT might
also play a role in developing methodologies for prevention
and public health studies, with a large potential for inno-
vation and new treatment alternatives. It will be crucial to
the success of such a global collaborative enterprise for BD
research to ensure adequate reliability of measures across
participating centres and consistent assessment procedures
( Chase et al., 2015 ; Manchia et al., 2013a ). 
5. Large-scale brain imaging phenotyping 
In contrast to most major somatic and neurological condi-
tions, whose incidence and prevalence increase with ad-
vancing age, the first manifestations of BD appear in ado-
lescence and in young adulthood ( Duffy et al., 2018 ). In-
deed, on average BD patients have their illness onset at 18
years of age ( Bauer et al., 2015 ). Thus, BD onset coincides
with profound neurodevelopmental changes and transitions
to new life-roles during adolescence. However, the mecha-
nisms underlying risk and resilience in the adolescent brain
are largely unknown, seriously impeding the development
of useful tools for early detection, individual prediction and
prevention. Downloaded for Anonymous User (n/a) at Aalborg Hospital from
For personal use only. No other uses without permission. CIndividual risk factors, together with critical time-periods
of susceptibility to environmental stressors during brain
development, influence the onset of BD. One important
research goal is to identify the “windows of opportunity”
where preventive strategies might be effective. This could
be investigated by the analysis of brain alterations in BD
patients during illness onset or peak risk for diagnostic
conversion (e.g. from major depressive disorder to BD).
International brain imaging efforts combining existing large-
scale brain imaging genetics databases ( n > 50,000) with
novel neuroimaging approaches may provide new insights
into the mechanisms underlying BD risk and resilience. In
this context, the Enhancing Neuro Imaging Genetics through
Meta-Analysis (ENIGMA) Bipolar Disorder Working Group was
formed to improve the statistical power, replication, and
generalizability of neuroimaging findings in BD research,
bringing together over 150 researchers from 20 countries.
By pooling data and resources, they have conducted the
largest neuroimaging studies of BD to date. The use of
standardized and publicly available processing and analysis
techniques ( http://enigma.ini.usc.edu/protocols/ ), has ad-
vanced large-scale meta- and mega-analyses of multimodal
brain MRI, clinical, and genetic data. Recent findings from
ENIGMA showed that BD was associated with lower cortical
thickness in bilateral frontal, temporal and parietal brain
regions, areas known to underlie the circuitry of emotion
and reward processing ( Hibar et al., 2018 ). Furthermore,
lithium use was associated with a widespread pattern of
thicker cortex, whereas anticonvulsant treatment was as-
sociated with lower cortical thickness ( Hibar et al., 2018 ).
The ENIGMA Bipolar Disorder Working Group also examined
case-control differences in subcortical volumes and found
that BD was associated with lower hippocampus, thalamus,
and amygdala volumes, as well as larger lateral ventricular
volumes, with small to moderate effect sizes ( Hibar et al.,
2016 ). In a recent follow-up study using machine learning
methods, these regional brain measures (cortical thickness,
cortical surface area, and subcortical volume) were ef-
fective in differentiating individuals with BD from healthy
controls at above chance accuracy in a large and hetero-
geneous sample ( N = 3020) ( Nunes et al., 2018 ). Future
multi-site brain-imaging machine learning studies are
moving beyond the use of engineered brain features (i.e.
volume, thickness, etc.) or site-level results, and towards
sharing of raw, individual subject data, where unsupervised
machine learning techniques may offer potential to better
stratify the heterogeneity in this complex disorder. 
6. Transforming big data discoveries to 
clinically relevant information 
Over the last decades, there have been numerous attempts
to stratify BD patients according to specific clinical char-
acteristics, such as, early age of onset ( Etain et al., 2010 ;
Manchia et al., 2017 , 2008 ), mood-incongruent psychosis
( Goes et al., 2007 ; Hamshere et al., 2009 ), and response to
lithium treatment ( Hou et al., 2016 ). Besides the dichotomy
of BD type I and II, and the possible exception of lithium-
responsive BD ( Nunes et al., 2019 ), the delineation of sub-
groups has had negligible impact on clinical decision making
or knowledge of the neurobiology of BD. Therefore, there ClinicalKey.com by Elsevier on September 03, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.





















































































































n  s an urgent need for operational, rational approaches that 
ake into account the impact of heterogeneity ( Nunes et al.,
020 ). This can be achieved with implementation of promis-
ng analytical methods, such as machine learning (and sta- 
istical learning) algorithms. These approaches applied to 
ig data are becoming increasingly relevant in psychiatric 
esearch ( Iniesta et al., 2016 ), allowing identification of rel-
vant predictors of specific outcomes, enabling risk strat- 
fication and facilitating individualized approaches in BD 
 Scott et al., 2019 ). Indeed, machine learning methods 
ave helped identifying predictors of treatment response 
 Nunes et al., 2019 ) and risk of episode recurrences in preg-
ancy and post-partum ( Di Florio et al., 2018 ). In addition,
ecent evidence shows that machine learning applied to 
rey matter and diffusion tensor neuroimaging data might 
e useful in differentiating major depressive disorder from 
D ( Vai et al., 2020 ). Furthermore, the application of these
lgorithms to proton magnetic resonance spectroscopy ( 1 H- 
RS) data has predicted diagnostic conversion to BD in high-
isk offspring ( Zhang et al., 2020 ). Finally, when these an-
lytical approaches were applied to daily self-assessments 
ollected via a smartphone-based system they predicted fu- 
ure mood scores, especially in short terms with low error
 Busk et al., 2020 ). Although these results point to clinical
elevance, at the moment they generally fall short of the ac-
uracy threshold needed for practical implementation and 
uch larger training datasets are required to achieve their 
ighest potential. Machine learning methods face important 
hallenges related to reproducibility of models and the de- 
irability for prediction based on mechanistic understand- 
ng rather than post hoc associations ( Beam et al., 2020 ).
o this end, future research directions should not only move 
oward increasing sample sizes, but also facilitating open 
cience (sharing codes and results) as we will discuss below. 
. Stratifying treatment – individualized 
esponse (precision medicine) 
ombining big data and individual level phenotyping is ex- 
remely valuable in order to characterize the unique, ad- 
itive and interactive effects of common and rare genetic 
ariants on the developing brain. This approach might en- 
ble the characterization of the common and unique spa- 
iotemporal brain characteristics across BD. By means of 
ovel data mining approaches based on machine learning 
nd pattern recognition, it is possible to use existing clini-
al imaging databases as training sets to identify clinically 
redictive brain patterns related to specific diagnostic cate- 
ories, and then apply these models to clinical test samples 
haracterized for treatment response or from RCTs. Indeed, 
sing machine learning algorithms applied to purely clini- 
al data, a recent study has been able to identify an accu-
ate predictive model of response to lithium treatment in 
,266 BD patients with a particularly low false-positive rate 
specificity 0.91) ( Nunes et al., 2019 ). This work underlines
ow clinical data can inform out-of-sample lithium response 
rediction to a clinically relevant degree ( Nunes et al.,
019 ). Similar approaches might be applied to brain imag-
ng also in combination with genetic and clinical data. Vari-
bility of brain structure related to common genetic vari- 
nts and polygenic scores can be applied to clinical data.Downloaded for Anonymous User (n/a) at Aalborg Hospital fr
For personal use only. No other uses without permission.his can include datasets collected in pharmacological tri- 
ls, or other types of treatment, in interventional studies 
nd prospective cohorts. 
This novel brain based individual level phenotyping - 
fingerprinting” - has great potential for stratification, 
efining prognosis and predicting treatment outcome. It 
epresents a unique example of the power offered in com-
ining large-scale normative data with rich clinical cohorts 
 Kaufmann et al., 2017 ). Jointly, this large-scale brain imag-
ng approach might provide a novel glimpse into disease 
echanisms and offer novel opportunities for brain-based 
tratification in future RCTs and clinical decision making. 
his big data approach applied to BD makes use of advanced
iostatistical tools to estimate normative models of brain 
evelopment based on huge datasets to form individual 
redictions in well-characterized clinical and prospective 
ohorts. This unique combination of hypothesis-generating 
ata mining and carefully characterized samples might al- 
ow the identification of phenotypes cutting across clinical 
haracteristics, enabling a new clinical nosology. Individual 
rain maps might be used against normative metrics in de-
elopment to estimate the probability of clinical traits and
utcomes. The vision is of an objective brain-based dissec- 
ion and prediction of complex traits. In addition, combining
ig data with a personalized phenotype approach has the
otential to investigate the sex specific characteristics of 
D. In fact, BD has a specific exacerbation/onset immedi-
tely after delivery and women might be at increased risk
uring menopause as well ( Bergink et al., 2016 ). 
. Smaller studies focussing on shorter term 
ffects and clinical trials 
ith the exception of lithium, there has been no medicine
eveloped with BD as its specific indication. Instead, inno-
ation has been limited to medicines already approved for
nother indication (epilepsy or schizophrenia) like carba- 
azepine, valproate, lamotrigine and the dopamine antag- 
nists/partial agonists. Clearly, we have lacked a convincing 
ccount of BD’s pathophysiology. It has also been a problem
hat an effective treatment has traditionally been trialled 
n the manic phase, the depressive phase and in relapse
revention. Such studies are immensely expensive and, in 
he case of relapse prevention, very time consuming. More-
ver, the development of long-term treatments – the great- 
st unmet need - may need to be de-coupled from the re-
uirement for short term efficacy. Effective anti-epileptic 
gents are not necessarily effective in status epilepticus, 
o state one obvious analogy. Recent research on mood sta-
ility in BD suggests that experimental medicine studies in
his disorder may be feasible, in which putative treatments
re studied over relatively short but intensively monitored 
ntervals in small groups of patients. More precise measure-
ent may allow the treatment effects of different drugs to
e compared in a more accurate way. Such an approach has
otential to assist companies wishing to evaluate new com-
ounds at the proof of concept stage. To give a single exam-
le, there is convergent evidence implicating calcium bio- 
hemistry in the neurobiology of BD ( Harrison et al., 2019 ).
xperimental studies are now entirely feasible to examine 
ovel drugs that modify calcium channels in the brain andom ClinicalKey.com by Elsevier on September 03, 2020.
 Copyright ©2020. Elsevier Inc. All rights reserved.

































































































an early confirmation of proof of concept would be essential
before the necessary investment for clinical development. 
However , it could also help in the re-purposing of existing
drugs ( Kessing et al., 2019 ). One of the most interesting re-
cent findings has been the observation that commonly used
drugs to treat physical disorders have an important effect
on psychiatric admissions. Intriguingly, 3–hydroxy–3-methyl-
glutaryl-coenzyme A reductase inhibitors (statins), L -Type
Calcium channel antagonists and biguanides are associated
with reduced admissions and reports of self-harm in BD (and
schizophrenia) ( Hayes et al., 2019 ). It will be fruitful to co-
ordinate single site/deep phenotyping studies with the big
data approach in an iterative manner. This can provide large
synergies, and help understand specific core pathology for
BD, such as, for example, the switch process. 
9. Moving forward - global bipolar disorder 
foundation 
Our conclusions are simple. An increase in funding for BD
would come at a highly opportune time given the seminal
advances promised for our understanding of the genetic and
brain basis of the disease and the obvious areas of unmet
clinical need. It is conceivable that in the next two-three
years, big data approach in BD research can provide new
insights that can be translated into clinical care. One exam-
ple is the application of polygenic risk scores for improved
diagnosis (e.g. distinguishing between unipolar and bipolar
depressive episodes). Another critical area for translation
is applying deep learning algorithms to the huge amount of
data collected via smartphones to improve forecasting of
new episodes (time of event) ( Busk et al., 2020 ; Faurholt-
Jepsen et al., 2019 ). In any instance, to spend money wisely,
requires a strategy for the goal of improved understanding
and treatment of BD based on the need for very large sam-
ples. The time may be right to attract philanthropic dona-
tions specifically for this end. 
9.1. The case for increased investment in BD now
BD has long attracted less support for research than
its economic impact appears to demand. The con-
trast with schizophrenia was noted almost 20 years ago
( Clement et al., 2003 ), and a systematic study of funding in
the UK suggested little has changed since ( MQ: Transform-
ing Mental Health, 2018 ). There is an extraordinary differ-
ence in money spent on research on psychiatric disorders
compared with cancer, cardiovascular disease and demen-
tia. There is every reason to think that we are at a scien-
tific crossroads now where a step change in research activ-
ity could yield the real returns on investment for BD that
are apparent for medical research in general ( Buxton et al.,
2008 ). 
9.2. A foundation for bipolar disorder 
Harnessing the brightest and the best across the globe will
require funding, but it will also benefit from greater co-
ordination and a sense of strategy. Previous similar attemptsDownloaded for Anonymous User (n/a) at Aalborg Hospital from
For personal use only. No other uses without permission. Cin the area of mood disorders include the Stanley Founda-
tion bipolar treatment outcome network ( Altshuler et al.,
2010 ), or the Mood Network of the patient-centred out-
comes research institute (PCORI) ( Selby et al., 2012 ).
These initiatives failed to obtain the critical mass, neces-
sary global involvement and scientific coordination that is
needed to form a “game-changing” effort in BD research.
However, we are not committed to a particular way of
achieving these ends. We should look for inspiration in the
private sector to the Michael J. Fox Foundation for Parkin-
son’s research ( https://www.michaeljfox.org ). Parkinson’s
disease offers some analogies with BD. The Fox Founda-
tion has massively raised awareness, provided leadership,
increased communication and has become a critical funding
vehicle for research. Cancer Research UK has been similarly
successful in a quite different disease area and has offered
world-class scientific direction in applying science to pathol-
ogy. Finally, a public-private partnership like UK Biobank
( www.ukbiobank.ac.uk ) offers a further successful example
of a generic platform that can serve a variety of different
chronic disease areas and is intended for use world-wide.
Unfortunately, it was not originally designed for diseases
with onset in adolescence and early adulthood, like BD and
the majority of psychiatric disorders. 
We must create an appropriate mechanism for BD re-
search which shamelessly copies what has worked well for
other diseases. For example, a Global Foundation for Bipolar
Disorder could provide a focus to bring government, industry
and philanthropy together in common cause. Alternatively,
there may already be more generic platforms to which BD
questions can be appended, as has happened for dementia
and UK Biobank, and from which a collaborative project can
develop. The best scientists need to be motivated to join
an international effort to beat BD. The human spirit will
provide the genius to do the rest. However, an insistence
on strategic direction and goal will be essential, which the
foundation could provide. 
9.3. Building an infrastructure and database 
Thus, we recommend a task force to integrate international
big data approach with real-world clinical interventions and
longitudinal cohorts. By coordinated action, it is possible to
obtain unique synergy by providing relevant clinical data to
the big data analytical approaches and integrate big data
results in a clinical trial network for the development of
personalized treatment regimens. This is recently made
possible due to technology development allowing high
throughput, large scale genetic and brain imaging data
collection, neurophysiological data as well as novel clinical
ICT tools for efficient, user-based clinical assessments. 
9.4. User involvement and dissemination 
A critical factor for success is a strong involvement of user
groups in the foundation and integration of dissemination
and public involvement with the research programs. Front-
line research discoveries in BD will, in addition to scientific
breakthroughs, help reduce stigma and increase awareness, ClinicalKey.com by Elsevier on September 03, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.






































































































E  hich can impact the lives of people currently affected by 
he disorder. 
.5. Open science 
here is rising concern about failures of replicability and 
ssociated waste of resources that seem to result from the
raditional way in which science has been conducted. The 
oundation can help establish a common database similar to 
he UK Biobank and a culture of open science in the BD re-
earch community. Open science generates transparent and 
ccessible knowledge that is shared and developed through 
ollaborative networks. Modern BD research in genetics and 
maging is showing the way this works. Open science would 
e a defining feature of work funded through the Bipolar
isorder Foundation. Lack of data sharing is one of the main
bstacles, which hinders the full realization of the potential 
f many research fields, which generate massive amounts 
f data per participants, such as brain imaging or genetics. 
onfidentiality and privacy issues are often cited as obsta- 
les to such sharing, especially for legacy datasets. These 
roblems must be taken seriously into account and the 
evelopment of adequate ethical-legal framework, which 
ould facilitate safe data sharing, should be a key and criti-
al component of such international endeavors. The benefit 
o the society in terms of development of new diagnostic or
rognostic tools for some of the most disabling and costly 
onditions will be potentially massive. 
.6. A roadmap to the global bipolar disorder 
oundation 
he creation of a Global Foundation will depend on funding,
oordination and the support of global network of experts in 
D, as well as user groups and their families. A Global Foun-
ation aims to promote the much-needed cross-fertilisation 
f expertise across leading world research institutions that 
s necessary to address the complexity of BD, overcome cur-
ent limitations of knowledge and advance research in this 
eld. We outline how ‘big data’ approaches can be an over-
eaching topic securing global, multidisciplinary and trans- 
ational research support. It will be of importance of ensur-
ng the participation of the main public and private stake- 
olders (NIH, EU, philanthropists), policymakers, as well as 
atients and family organizations. A Global Foundation will 
lay ideally a pivotal role in disseminating the outputs pro-
uced through workshops, seminars and symposia organised 
t conferences. One specific task will be to support young 
linicians and researchers with an interest in diverse areas 
f BD research.”
0. Conclusion 
e have argued that BD is an extremely significant chal- 
enge for the healthcare and the socio-economic system at 
 global level. We believe the time is right for a step change
n our approach to understanding, preventing and treating 
t effectively. This can be achieved toward an innovative Downloaded for Anonymous User (n/a) at Aalborg Hospital fr
For personal use only. No other uses without permission.odel integrating novel big data approaches with clinical 
tudies. 
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